Published: 26 October 2018

Horizon 2020 stem cell study moves to clinical trial phase

The NEPHSTROM study uses next generation Mesenchymal Stromal Cell (MSC) therapy in an effort to improve kidney function. If successful, the therapy could provide patients with an alternative to dialysis or kidney transplant.

The project aims to enrol up to 48 patients in a double-blind placebo controlled trial, across 4 centres; HRB Clinical Research Facility, Galway, University Hospital Birmingham NHS Foundation Trust, UK, Health and Social Care Trust, Belfast and The Mario Negri Institute, Italy

The Mesenchymal Stromal Cell (MSC) therapy has been found to dramatically improve kidney function in pre-clinical models of diabetes. The therapy will be trialled on patients with kidney disease whose previous treatments have failed.

NEPHSTROM is a €6 million, four-year long Horizon 2020 project that is led by Professor Tim O’Brien at NUI Galway.  

For more information see:
http://nephstrom.eu/